Dear colleagues,
It gives me pleasure to share with you our report of this year’s joint ECTRIMS and ACTRIMS meeting, MSMilan 2023.
Approximately 8,000 researchers, clinician scientists, and nurses working in the field of multiple sclerosis gathered in Milan to discuss the newest developments in pertinent areas, from basic science to clinical management.
We selected a range of contributions which we think were particularly important.
I am confident you share the excitement about the numerous advances presented in Milan, which are reflected in this report.
Yours sincerely,
Prof. Hans-Peter Hartung
FRCP FEAN FAAN FANA
Biography
Prof. Hartung is currently Professor of Neurology at Heinrich-Heine-University Düsseldorf, Honorary Professor at Brain and Mind Center, University of Sydney, Visiting Professor at Medical University Vienna and Palacky University Olomouc. He was chairman of the Department of Neurology, Heinrich-Heine-University Düsseldorf from 2001-2020, director of the Center for Neurology and Neuropsychiatry from 2012-2020 and director of the Department of Conservative Medicine from 2012-2019.
Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies, development of new immunological, neuroprotective and neural repair promoting strategies. He has (co-)authored more than 950 articles in peer-reviewed journals and 100 book chapters. He has been involved as member of the Steering Committee in numerous international multicentre therapeutic phase 2 and 3 trials in multiple sclerosis, Guillain-Barré Syndrome and CIDP.
He was President of ECTRIMS and has served/ serves amongst others on the executive boards of the European Charcot Foundation, the European Neurological Society, and the International Multiple Sclerosis Cognition Society (IMSCOGS). He is/was also member of the Editorial Board of a number of international journals. Prof. Hartung is a Fellow of the AAN and EAN, and has been chair/ member of the management group of the EAN scientific panels on general neurology and multiple sclerosis. He is Corresponding and Honorary Fellow of several international societies.
Conflict of Interest Statement:
Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, Teva, TG Therapeutics, and Viela Bio, with approval by the Rector of Heinrich-Heine University.
Posted on
Previous Article
« Telerehabilitation effective in improving MS symptoms in patients with moderate disability Next Article
Sickness absence rate increases years before clinical onset of MS »
« Telerehabilitation effective in improving MS symptoms in patients with moderate disability Next Article
Sickness absence rate increases years before clinical onset of MS »
Table of Contents: MSMilan 2023
Featured articles
Letter from the Editor
Real-world data supports ocrelizumab prior to conception
Progressive MS
Early initiation of highly active treatment associated with a lower risk of SPMS
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients
Paediatric MS
Prioritising high efficacy therapies in children with MS
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity
NMOSD & MOGAD
An update on evolving treatment algorithms for NMOSD and MOGAD
Women’s Health
Rate of grey matter brain atrophy accelerates after menopause
Real-world data supports ocrelizumab prior to conception
Miscellaneous
New insights into the contribution of EBV to MS pathogenesis
COVID-19 infection associated with higher MS relapse rate
Telerehabilitation effective in improving MS symptoms in patients with moderate disability
Curing MS
Understanding what an MS cure means and what it takes
Prodromal MS
Progressive brain tissue loss precedes the onset of clinical MS by years
Sickness absence rate increases years before clinical onset of MS
Treatment Trials and MS Strategies
Early intensive treatment enhances long-term clinical outcomes
Oral glycolipid shows promise in the treatment of MS, especially SPMS
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients
Biomarkers & Imaging
χ-separation can assess the effects of tissue destruction in early MS lesions
High sGFAP levels are associated with disease progression, independent of NfL or relapse activity
Broad rim lesions correlate with a rapidly progressive MS phenotype
Smouldering inflammation detectable even in the earliest stages of MS
Related Articles
November 25, 2020
Amantadine, modafinil, and methylphenidate for MS-related fatigue
July 30, 2019
No increased MS relapse risk postpartum
June 16, 2021
MS therapies influence COVID-19 severity
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy